Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: Updated results of the MM87 prospective randomized protocol

Age could influence the prognosis of multiple myeloma patients treated with conventional chemotherapy. Between January 1987 and March 1990, 341 consecutive previously untreated patients with multiple myeloma received chemotherapy within the prospective, multicentre, randomized Protocol MM87. Survival was evaluated in patients aged > or ≤ 66 years (the median age for the whole series) and in a subgroup of patients aged <55 years. These groups were similar for main clinical characteristics, including results of cytostatic treatment. As of May 1996, 271 (79%) of the 341 patients had died, and median follow-up of the 70 (21%) living patients was 82 months. Overall, younger patients survived longer than older ones. In fact, in patients > and ≤ 66 years, median survival was 31 and 44 months (P <0.00095) and the percentage of patients surviving over 72 months was 17% and 32% (P = 0.0018) respectively; in patients <55 years, these figures were 57 months and 35% respectively (P = 0.02 and 0.01, with respect to patients aged ≤ 55 years). In all groups, about 50% of the patients surviving over 72 months had stage I disease. For multiple myeloma patients treated with chemotherapy, survival is favourably affected by relatively young age and early stage of disease.